COA Available
Performance In Stock Research Use Only
CJC-1295 + Ipamorelin
10mg · Lyophilized Powder · Purity ≥98%
This combination research formulation contains CJC-1295 without DAC (Modified GRF 1-29) and Ipamorelin in a single vial, providing simultaneous GHRH receptor and GHS-R1a receptor ligands for research examining dual-pathway GH axis engagement. The formulation is studied in preclinical models investigating synergistic hypothalamic-pituitary signalling resulting from concurrent GHRH receptor and ghrelin receptor activation.
$75.99 CAD
Purchase Options
Subscriptions can be managed from your customer account. Prices in CAD.
Research Overview
CJC-1295 without DAC and Ipamorelin act on distinct but converging receptor populations within the anterior pituitary — GHRH-R and GHS-R1a respectively — with preclinical data suggesting that their co-administration produces additive or synergistic GH release compared to either compound alone in animal models. This combination vial simplifies research workflows that require concurrent presentation of both receptor agonists in standardised molar quantities. Each batch is HPLC-verified for both peptide components and supplied with a combined COA. Supplied exclusively for laboratory and research use.
Research into dual GHRH/GHS pathway activation has used CJC-1295 + Ipamorelin co-treatment to characterise signal integration at the somatotroph level and to model physiological GH pulse amplitude in preclinical systems. The combination has also been employed in receptor pharmacology studies to distinguish GHRH-R– and GHS-R1a–dependent contributions to GH secretion through selective antagonism experiments. Published preclinical data support the mechanistic rationale for additive pituitary signalling when both receptor pathways are engaged concurrently. All outcomes referenced pertain to preclinical models and do not constitute evidence of clinical efficacy or safety in humans.
Specifications
| Compound | CJC-1295 + Ipamorelin |
| Format | Lyophilized Powder |
| Size | 10mg |
| Purity (HPLC) | ≥98% |
| Item # | BME-CJC129-A |
| Storage | −20°C, dry, dark |
| Price (CAD) | $75.99 |
COA / Testing
Batch documentation and third-party testing information are available for batch BME-CJC129-A. COA previews appear only when documentation exists for the active batch.
Storage & Handling
Store the lyophilised CJC-1295 + Ipamorelin combination vial at −20°C in its original sealed container, protected from moisture and light. Avoid repeated freeze-thaw cycles to preserve the integrity of both peptide components. After reconstitution, aliquot into single-use volumes and store at −80°C; refer to the lot-specific COA for validated stability data for each component.
Shipping & Returns
Orders are processed on business days. Packaging is selected to maintain compound integrity in transit. Shipping timelines and return conditions are outlined in full in the Shipping & Returns policy — review before checkout if you have specific requirements. For orders with time-sensitive research schedules, contact support before placing your order.
Research Use Disclaimer
This product is supplied strictly for in-vitro and laboratory research use. It is not a drug, food supplement, or cosmetic and is not approved for human or veterinary clinical applications, diagnostics, or therapeutic use. Researchers are responsible for compliance with all applicable institutional and regulatory requirements in their jurisdiction.
Preparation Reference Guide
Research Solution Reference Calculator
Pre-filled with 10mg. Enter your solvent volume and target amount to see concentration and units on a U-100 syringe scale.
Concentration—
Volume to draw—
Syringe units (U-100)—
Per insulin unit—
For research-use calculations only. Always verify measurements independently — not medical guidance.
Questions before you order?
Browse the FAQ for documentation, storage, and sourcing answers, or contact our support team directly. We aim to respond to all research procurement inquiries within one business day.
Related
